You can also read the IBTA e-News July 2019 edition in full online here.
Some of the highlights from this month's round-up:
- All.Can international, of which the IBTA is a founding member, has launched a report entitled "Patient insights on cancer care: opportunities for improving efficiency". It reveals findings from an international survey on patient perspectives of inefficiencies in cancer care.
- The US Centers for Medicare & Medicaid Services (CMS) has established a 2019 monthly fee schedule amount for Optune.
- Researchers have profiled gene expression in more than 24,000 tumour cells from 20 adult and eight paediatric glioblastoma patients and also analysed glioblastoma models in the lab. The results also show that glioblastoma cells are remarkably flexible, meaning they can switch between the four states.
- In a mouse study reported in Nature Biotechnology, researchers have created a new immune therapy based on chimeric antigen receptor-T cells that have been genetically engineered to secrete bi-specific T-cell engager anitbodies.
- Ziopharm Oncology has announced a phase 2 clinical trial in the US evaluating its Controlled IL-12 gene therapy platform in combination with the PD-1 inhibitor Libtayo in recurrent or progressive glioblastoma. This trial builds on a previous Phase 1 trial combining the Controlled IL-12 platform with nivolumab, also in recurrent glioblastoma.
- A partnership between the University of Nottingham in the UK and Johns Hopkins University in the US has evaluated the therapeutic potential of a biodegradable and temperature-sensitive polymer called PLGA/PEG.
- CarThera, a French company designing and developing ultrasound-based medical devices to treat brain disorders, has launched a Phase 1/2a clinical trial for recurrent glioblastoma in France and the US. Several minutes of low-intensity ultrasound temporarily opens the blood-brain barrier for six hours, potentially improving the ability of medicines to cross into the brain and increase their effectiveness.
Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.
To see an archive of existing e-News issues, click here.